UNSPSC 51182059: Nandrolone furylpropionate

This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C25H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W1309SNY8U, chemically known as estr-4-en-3-one, 17-(3-(2-furanyl)-1-oxopropoxy)-, (17.beta.)-, but more generally known as nandrolone furylpropionate, which bears US NIH Compound Identifier 111318. European Medicines Agency schedules nandrolone furylpropionate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09148MIG.

Most nations, for tariff purposes, schedule nandrolone furylpropionate under HS 29372900. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4CCCO4)CCC5=CC(=O)CC[C@H]35.

UNSPSC 51182059 Nandrolone furylpropionate, a Commodity code, encompasses anabolic steroids and pharmaceutical compounds supplied to state and local government health systems, correctional facilities, and other public agencies through cooperative purchasing vehicles. State and local procurement under this code flows primarily through multistate cooperative alliances rather than individual jurisdiction direct buys, with participating states and their subordinate agencies—including departments of health, corrections, and state hospital systems—aggregating demand to negotiate volume pricing and ensure supply chain compliance with FDA requirements and Drug Supply Chain Security Act certification.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026. The solicitation requires vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with pricing weighted 75 percent in evaluation, compliance with cGMP and DSCSA standards, EDI capability, and contractual relationships with at least two of the three wholesalers. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and patient safety, with contract terms of two years for new responders and optional extensions at MMCAP's sole discretion, while incumbent vendors' agreements extend through June 30, 2028. Vendors must maintain commercial general liability of $5,000,000 per occurrence and professional liability of $2,000,000, with performance penalties ranging from $200 to $1,500 per violation for late reporting or missed onboarding timelines.